The San Antonio Breast Cancer Symposium (SABCS) will be held in San Antonio, Texas from December 9–13. We have assembled a pre- meeting listing of highlights based on presentation titles that were released. Abstracts will not be publicly available to non-SABCS attendees until after the conclusion of the meeting.

We expect top-line read-outs from several combination trials of multiple targeted agents, most notably for HER2+ tumors (everolimus or ARRY-380 with HER2-targeted antibodies) and for ER+ tumors (various tyrosine kinase inhibitors with aromatase inhibitors). Treatment with mechanistically validated inhibitor combinations may increase efficacy without exceeding the maximum tolerated doses of the individual drugs. We also expect data from two androgen receptor (AR) inhibitors; a high percentage of breast cancer tumors display AR, and high levels of AR expression may allow cells to circumvent other hormone receptor-mediated signaling pathways. Furthermore, we may see top-line breast cancer-specific efficacy data for the PD-1 inhibitor pembrolizumab (Keytruda, NVS), which was recently approved for refractory metastatic melanoma.

For our disclosures, please read the BioMedTracker Research Standards.